Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (infliximab-abda) subsequently launched in July 2017. Waves 1 and 2 of this series track Inflectra’s awareness and uptake since launch, while Wave 3 also incorporates Renflexis. Along with awareness, familiarity, and perceptions of biosimilars, our research explores the drivers and barriers behind uptake of both Inflectra and Renflexis. Promotional efforts are also explored, as well as prescriber and nonprescriber profiles, and benchmarking comparisons against other available biosimilars, to better understand the dynamics of the U.S. biosimilars market.
Are U.S. physicians aware of Inflectra and Renflexis?
What are the drivers to prescribing an infliximab biosimilar? What is the level of Inflectra and Renflexis use, and how is that changing over time?
Are physicians’ opinions of biosimilars changing?
Have physicians experienced pressures to prescribe Inflectra or Renflexis to patients?
What promotional messages are sales representatives employing for Inflectra, Renflexis, and Remicade?
How does formulary placement of Inflectra and Renflexis compare with Remicade, and does this change over time?
Markets covered: United States.
Primary research: Survey of 92 U.S. rheumatologists, gastroenterologists, and dermatologists.
Expected Impact of Patient Healthcare Coverage on Inflectra and Renflexis Uptake
Physicians' Expectation of Impact of Patients' Healthcare Coverage on Inflectra Uptake
Physicians' Expectation of Impact of Patients' Healthcare Coverage on Uptake of Renflexis
Reasons Why Physicians Think Inflectrau2019s Uptake Will Be Most Rapid Among Patients on Commercial Plans
Reasons Why Physicians Think Inflectrau2019s Uptake Will Be Most Rapid Among Patients on Government Plans
Reasons Why Physicians Think Uptake of Renflexis Will Be Most Rapid Among Patients on Commercial Plans
Reasons Why Physicians Think Uptake of Renflexis Will Be Most Rapid Among Patients on Government Plans
Background on the U.S. Infliximab Market
Product Information: Remicade, Inflectra, and Renflexis
List Price for Infliximab
Market Background: Celltrion's and Samsung Bioepis' Partners for Infliximab Biosimilars
The Celltrion Partnership Network
Timeline of Milestones for Inflectra
Timeline of Milestones for Renflexis
Biologics Approved for Rheumatic, Inflammatory Bowel, and Psoriatic Diseases in the United States
Assumptions Supporting U.S. Launch Date Estimates for Future Infliximab Biosimilars
U.S. Launch Date Estimates for Future Infliximab Biosimilars
Clinical Trial Information in Which Inflectra Was Studied Prior to FDA Approval
Clinical Trial Information in Which Renflexis Was Studied Prior to FDA Approval
Methodology and Objectives
Number of Study Participants
Significance Testing in This Study
Physicians' Primary Specialty
Mean Number of Years in Practice
Number of Years in Practice
Distribution of Respondents by Region
Number of Adult Patients Under Management per Month
Number of Pediatric Patients Under Management per Month
Available Biologics Prescribed for Rheumatoid Arthritis by Rheumatologists
Available Biologics Prescribed for Psoriatic Arthritis by Rheumatologists
Types of Patients Treated by Gastroenterologists
Available Biologics Prescribed for Crohn's Disease by Gastroenterologists
Available Biologics Prescribed for Ulcerative Colitis by Gastroenterologists
Available Biologics Prescribed for Psoriasis by Dermatologists
Jimmy Jacob, Ph.D.
Jimmy Jacob, Ph.D., is a business development manager at DRG, part of Clarivate. Prior to joining DRG, he was a scientist at Medimmune and Horizon Discovery. He received his master’s degree in biotechnology from the University of Dundee and his Ph.D. from Imperial College London. His Ph.D. work involved identifying novel molecules that regulated estrogen receptor-alpha in breast cancer.